PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY
Orgo-Life the new way to the future Advertising by AdpathwayPharmacological activation of the G-protein-coupled receptor GPR39 robustly protects against metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis while promoting the regression of established disease in preclinical mouse models, according to a study published in Molecular Medicine. Researchers evaluated the selective GPR39 agonist compound designated TM-N1324 in diet-induced disease models, observing therapeutic effects across both preventive and disease-regression experimental settings.
Prior experimental evidence established that deficiency of the GPR39 receptor predisposes organisms to obesity and hepatosteatosis. Despite this observed link, the specific hepatic functions of the receptor and its viability as a therapeutic target had remained poorly understood prior to the current investigation.
To determine whether pharmacological intervention could counter disease development, the research team administered the selective agonist TM-N1324 to diet-induced mouse models of MASLD and MASH. The experimental design assessed both systemic outcomes and liver-specific consequences, while also examining the activation of specific hepatic signaling pathways. Furthermore, the investigators evaluated GPR39 dependency, sex dependency, and body-weight dependency by directly comparing treatment responses across relevant experimental groups.
Systemic evaluations revealed that TM-N1324 administration improved several cardinal features of metabolic syndrome in the treated animals. Documented improvements included enhanced glucose tolerance, improved cholesterol metabolism, and reduced adiposity. In addition, treatment altered the respiratory exchange ratio in a manner consistent with a whole-body shift in substrate utilization toward fat oxidation, all while successfully maintaining favorable circulating triglyceride profiles throughout the intervention.
The compound enhanced hepatic ERK1/2 signaling and SREBP2 levels while significantly reducing hepatic triglyceride content.
Mechanistic assays further revealed that TM-N1324 increased hepatic PARylation, with researchers determining that intact hepatocyte NAD+ metabolism was strictly required for the agonist to confer its liver-protective effects. The hepatic responses induced by TM-N1324 were confirmed to be mediated specifically through the GPR39 receptor. Crucially, the therapeutic effects operated independently of animal sex and baseline body weight across the tested cohorts.
The study authors conclude that targeting GPR39 with pharmacological agonists represents a therapeutically actionable intervention capable of mitigating MASLD and MASH and improving metabolic syndrome features.
Subject of Research: Preclinical evaluation of GPR39 agonist TM-N1324 in mouse models of MASLD and MASH
Article Title: Pharmacological GPR39 activation protects against MASLD/MASH and improves metabolic syndrome features: a preclinical study in diet-induced mouse models
Article References: Laitakari, A., Jacobsen, J. C. B., Ye, Z., Poulsen, S. S., Cuenco, J., Klotz, S., Hassing, A. S., Liu, L., Lin, C., Phlairaharn, T., Cucchiara, C. M., Brethvad, A. O., Bach, A., Holst, B., Treebak, J. T., Olsen, J. V., Sakamoto, K., & Frimurer, T. M. (2026). Pharmacological GPR39 activation protects against MASLD/MASH and improves metabolic syndrome features: a preclinical study in diet-induced mouse models. Molecular Medicine. https://doi.org/10.1186/s10020-026-01662-7
Image Credits: AI Generated
DOI: 10.1186/s10020-026-01662-7
Keywords: GPR39, TM-N1324, MASLD, MASH, Metabolic Syndrome, Hepatosteatosis, Hepatic Triglycerides, Glucose Tolerance, Adiposity, Respiratory Exchange Ratio, ERK1/2 Signaling, SREBP2, Apolipoprotein B, VLDL, PARylation, NAD+ Metabolism, Preclinical Research


10 hours ago
8




















English (US) ·
French (CA) ·